Search Results for "liraglutide"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for liraglutide. Results 31 to 33 of 33 total matches.
See also: Victoza

Expanded Table: Some Available Insulins for Type 2 Diabetes (online only)

   
The Medical Letter on Drugs and Therapeutics • May 06, 2019  (Issue 1571)
Insulin degludec/liraglutide – Xultophy (Novo Nordisk) 100 units/3.6 mg/mL 3 mL prefilled pens Insulin ...
View the Expanded Table: Some Available Insulins
Med Lett Drugs Ther. 2019 May 6;61(1571):e73-7 |  Show IntroductionHide Introduction

In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease

   
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023  (Issue 1668)
cardiovascular benefits (dulaglutide, liraglutide, or subcutaneous semaglutide) can be used if an SGLT2 ...
Recently published guidelines from the American Diabetes Association (ADA) and the Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group recommend addition of the oral nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) to standard treatment in patients with type 2 diabetes and chronic kidney disease (CKD).
Med Lett Drugs Ther. 2023 Jan 23;65(1668):15-6   doi:10.58347/tml.2023.1668e |  Show IntroductionHide Introduction

Contrave - A Combination of Bupropion and Naltrexone for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Nov 10, 2014  (Issue 1455)
receptor agonist liraglutide, which is approved for treatment of type 2 diabetes as Victoza, is currently ...
The FDA has approved a fixed-dose combination of the opioid receptor antagonist naltrexone (ReVia, and others) and the antidepressant and smoking cessation agent bupropion (Wellbutrin SR, Zyban, and others), as Contrave (Orexigen/Takeda) for weight loss. The combination was approved for use as an adjunct to diet and increased physical activity in patients with a body mass index (BMI) ≥30 kg/m2 or a BMI ≥27 kg/m2 and one or more weight-related comorbidities such as hypertension, diabetes, or dyslipidemia. Naltrexone/bupropion is not a controlled...
Med Lett Drugs Ther. 2014 Nov 10;56(1455):112-4 |  Show IntroductionHide Introduction